166 related articles for article (PubMed ID: 25246274)
1. The novel C24D synthetic polypeptide inhibits binding of placenta immunosuppressive ferritin to human T cells and elicits anti-breast cancer immunity in vitro and in vivo.
Solodeev I; Zahalka MA; Moroz C
Neoplasia; 2014 Sep; 16(9):741-50. PubMed ID: 25246274
[TBL] [Abstract][Full Text] [Related]
2. Antibodies to placental immunoregulatory ferritin with transfer of polyclonal lymphocytes arrest MCF-7 human breast cancer growth in a nude mouse model.
Halpern M; Zahalka MA; Traub L; Moroz C
Neoplasia; 2007 Jun; 9(6):487-94. PubMed ID: 17603631
[TBL] [Abstract][Full Text] [Related]
3. PLIF, a novel human ferritin subunit from placenta with immunosuppressive activity.
Moroz C; Traub L; Maymon R; Zahalka MA
J Biol Chem; 2002 Apr; 277(15):12901-5. PubMed ID: 11821435
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel HLA-A2-restricted cytotoxic T lymphocyte epitope from cancer-testis antigen PLAC1 in breast cancer.
Liu W; Zhai M; Wu Z; Qi Y; Wu Y; Dai C; Sun M; Li L; Gao Y
Amino Acids; 2012 Jun; 42(6):2257-65. PubMed ID: 21710262
[TBL] [Abstract][Full Text] [Related]
5. A novel role for an old target: CD45 for breast cancer immunotherapy.
Raiter A; Zlotnik O; Lipovetsky J; Mugami S; Dar S; Lubin I; Sharon E; Cohen CJ; Yerushalmi R
Oncoimmunology; 2021 May; 10(1):1929725. PubMed ID: 34104545
[TBL] [Abstract][Full Text] [Related]
6. PLIF induces IL-10 production in monocytes: a calmodulin-p38 mitogen-activated protein kinase-dependent pathway.
Zahalka MA; Barak V; Traub L; Moroz C
FASEB J; 2003 May; 17(8):955-7. PubMed ID: 12670872
[TBL] [Abstract][Full Text] [Related]
7. Placental immunomodulator ferritin, a novel immunoregulator, suppresses experimental arthritis.
Weinberger A; Halpern M; Zahalka MA; Quintana F; Traub L; Moroz C
Arthritis Rheum; 2003 Mar; 48(3):846-53. PubMed ID: 12632441
[TBL] [Abstract][Full Text] [Related]
8. Induction of antitumor cytotoxic lymphocytes using engineered human primary blood dendritic cells.
Wu L; Zhang H; Jiang Y; Gallo RC; Cheng H
Proc Natl Acad Sci U S A; 2018 May; 115(19):E4453-E4462. PubMed ID: 29674449
[TBL] [Abstract][Full Text] [Related]
9. Generation of Melan-A/MART-1-specific CD8+ cytotoxic T lymphocytes from human naive precursors: helper effect requirement for efficient primary cytotoxic T lymphocyte induction in vitro.
Ostankovitch M; Le Gal FA; Connan F; Chassin D; Choppin J; Guillet JG
Int J Cancer; 1997 Sep; 72(6):987-94. PubMed ID: 9378563
[TBL] [Abstract][Full Text] [Related]
10. A novel HLA-A2-restricted CTL epitope of tumor-associated antigen L6 can inhibit tumor growth in vivo.
Tu SH; Huang HI; Lin SI; Liu HY; Sher YP; Chiang SK; Chong P; Roffler S; Tseng GC; Chen HW; Liu SJ
J Immunother; 2012 Apr; 35(3):235-44. PubMed ID: 22421941
[TBL] [Abstract][Full Text] [Related]
11. Treatment of human bone marrow with recombinant placenta immunoregulator ferritin results in myelopoiesis and T-cell suppression through modulation of the cytokine-chemokine networks.
Moroz C; Grunspan A; Zahalka MA; Traub L; Kodman Y; Yaniv I
Exp Hematol; 2006 Feb; 34(2):159-66. PubMed ID: 16459184
[TBL] [Abstract][Full Text] [Related]
12. A CD80-transfected human breast cancer cell variant induces HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as well as in vivo.
Gückel B; Stumm S; Rentzsch C; Marmé A; Mannhardt G; Wallwiener D
Cancer Immunol Immunother; 2005 Feb; 54(2):129-40. PubMed ID: 15365776
[TBL] [Abstract][Full Text] [Related]
13. Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes.
Kuznetsova M; Lopatnikova J; Khantakova J; Maksyutov R; Maksyutov A; Sennikov S
BMC Immunol; 2017 Jun; 18(1):31. PubMed ID: 28633645
[TBL] [Abstract][Full Text] [Related]
14. Recombinant mammaglobin A adenovirus-infected dendritic cells induce mammaglobin A-specific CD8+ cytotoxic T lymphocytes against breast cancer cells in vitro.
Cui H; Zhang W; Hu W; Liu K; Wang T; Ma N; Liu X; Liu Y; Jiang Y
PLoS One; 2013; 8(5):e63055. PubMed ID: 23650543
[TBL] [Abstract][Full Text] [Related]
15. Induction of antitumor cytotoxic T lymphocytes from the peripheral blood mononuclear cells of cancer patients using HLA-A2-restricted MAGE-3 peptide in vitro.
Fujie T; Tanaka F; Mori M; Takesako K; Sugimachi K; Akiyoshi T
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2425-30. PubMed ID: 9815643
[TBL] [Abstract][Full Text] [Related]
16. HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients' Response to Neoadjuvant Chemotherapy.
Saraiva DP; Jacinto A; Borralho P; Braga S; Cabral MG
Front Immunol; 2018; 9():2605. PubMed ID: 30555458
[TBL] [Abstract][Full Text] [Related]
17. Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors.
Sotiropoulou PA; Perez SA; Voelter V; Echner H; Missitzis I; Tsavaris NB; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2003 Dec; 52(12):771-9. PubMed ID: 13680193
[TBL] [Abstract][Full Text] [Related]
18. Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors.
Gritzapis AD; Sotiriadou NN; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2004 Nov; 53(11):1027-40. PubMed ID: 15164233
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine treatment enhanced the anti-tumor effect of cytokine induced killer cells by depletion of CD4
Zhao P; Zhu D; Zhang Z; Han B; Gao D; Wei X; Xie X; Li C; Sun W; Wang Q; Guo Q
Immunol Lett; 2017 Jan; 181():36-44. PubMed ID: 27867030
[TBL] [Abstract][Full Text] [Related]
20. Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity.
Amrolia PJ; Reid SD; Gao L; Schultheis B; Dotti G; Brenner MK; Melo JV; Goldman JM; Stauss HJ
Blood; 2003 Feb; 101(3):1007-14. PubMed ID: 12393606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
